Article
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood - 7 Jul 2022
Tashakori Mehrnoosh, Kadia Tapan, Loghavi Sanam, Daver Naval, Kanagal-Shamanna Rashmi, Pierce Sherry, Sui Dawen, Wei Peng, Khodakarami Farnoosh, Tang Zhenya, Routbort Mark, Bivins Carol A, Jabbour Elias J, Medeiros L Jeffrey, Bhalla Kapil, Kantarjian Hagop M, Ravandi Farhad, Khoury Joseph D
Abstract excerpt
Mutant TP53 is an adverse risk factor in acute myeloid leukemia (AML), but large-scale integrated genomic-proteomic analyses of TP53 alterations in patients with AML remain limited. We analyzed TP53 mutational status, copy number (CN), and protein expression data in AML (N = 528) and provide a compilation of mutation sites and types across disease subgroups among treated and untreated patients. Our analysis shows...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.